Veeva Systems Inc. (VEEV) is a provider of cloud-based software for the life sciences industry, not an exchange-traded fund. The $345 central target was calculated as the arithmetic mean of 12 current analyst price targets identified by firm, analyst, and date, published between November 6 and November 19, 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Those targets run from $275 (Morgan Stanley, Hold) to $400 (Wells Fargo, Buy), with a cluster of bullish estimates between $360 and $375 from firms including BTIG, Truist, Jefferies, Barclays, and Needham. Neutral-to-cautious views sit lower, with BMO Capital at $300, UBS at $310, and Canaccord Genuity at $315. The mean of the 12 targets is approximately $344.58, rounded to $345. Broader aggregator tallies that include additional bearish estimates show a wider low near $180, which underscores how divided the Street remains.
The overall rating skew is bullish — most firms rate the stock Buy or Overweight — but the wide dispersion means this is not a tightly clustered consensus. Bullish analysts emphasize durable subscription revenue, market-share gains in life sciences CRM, and new AI-related products, while cautious analysts argue that core products are maturing and that much of the optimism is already reflected in the valuation.
VEEV closed near $262.92 on November 19, 2026, a sharp single-session decline from the prior close of $277.20. Reaching $345 would require a gain of roughly 31%, a substantial move by most standards. The shares have traded in a wide 52-week range of about $148.05 to $325.99, meaning the stock has already demonstrated the capacity for large swings in both directions.
The path toward the target rests on sustained execution: Veeva reported revenue of $927.96 million for its July-quarter, up about 17.6% year over year and above consensus estimates, and it has raised its full-year fiscal 2027 EPS guidance to $9.21, well above the roughly $8.58 consensus. The company trades at a trailing P/E near 43 and a forward P/E near 27, so continued estimate increases, rather than multiple expansion alone, would be the more durable route higher.
Several verified factors support the bullish case. Revenue growth remains in the mid-teens, gross margins are near 75%, and Veeva continues to convert large pharmaceutical customers to Vault CRM — recent wins include UCB, Amgen, and Roche Pharma. The company has also been rolling out AI-driven products such as Falcon Safety and agentic biopharma tools, which analysts view as potential new growth vectors. Management's decision to raise full-year guidance, combined with a reported $2 billion buyback authorization, signals confidence in cash generation and profitability.
The principal obstacle is valuation. At a trailing P/E in the low 40s, the stock leaves limited room for error, and any deceleration in revenue growth could compress the multiple. Insider selling has picked up, with several officers and directors reducing positions in recent months, and short interest remains elevated. Competition in life sciences software is intensifying, and some analysts — including a Sell-rated view from Goldman Sachs earlier in 2026 — argue that core Commercial products are maturing and that new product ramps lack visibility, creating downside risk to consensus expectations.
The 52-week high near $326 is a meaningful resistance level, and $300 has served as a psychological battleground in recent sessions. On the downside, the stock's recovery from its April/June 2026 lows near $148 means a zone of support exists in the $250 area, with further support around $200. A sustained move toward $345 would first require the stock to reclaim and hold above $300, then break through the prior high near $326.
Analyst price targets generally reflect a research horizon of about 12 months, though the horizon is not always stated explicitly and varies by firm. Investors tracking whether VEEV can move toward $345 should monitor the December 3, 2026 earnings report and guidance update, any further analyst target revisions, the pace of Vault CRM customer migrations, developments in AI products, and broader software-sector multiple compression. Macro conditions, including interest-rate expectations, also matter for a stock with a premium valuation.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors watching VEEV, these signals offer a data-driven complement to fundamental research. I find this helpful when I want to see how the broader market is interpreting the same data points I review manually.
The $345 central target is an analyst-derived average — the mean of 12 current, verified price targets — and it implies a substantial move of roughly 31% from the recent price near $262.92. Support comes from solid revenue growth, raised guidance, and large-customer CRM migrations, while the principal obstacles are a premium valuation, insider selling, and disagreement about whether growth can be sustained as core products mature. The unusually wide analyst range, from $275 to $400, indicates that even professionals hold sharply divergent views. Reaching $345 is plausible only if execution stays strong and estimates keep rising, but it is not a guaranteed outcome and should not be treated as one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VEEV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 54 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 69%.
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 133 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry